Skip to main content
Premium Trial:

Request an Annual Quote

Mitomics Realigns, Eliminates Eight Positions

NEW YORK (GenomeWeb News) – Mitochondrial DNA-based test developer Mitomics today announced a realignment of its product development operations, resulting in the elimination of eight jobs.

Chief Laboratory Officer Jennifer Creed will also now lead end-to-end product development for the company based in Thunder Bay, Ontario.

In a statement, Mitomics President and CEO Robert Poulter said that the firm "continues to face tremendous opportunity and potential for growth in the diagnostics arena."

The company's lead product is its Prostate Core Mitomic Test, or PCMT, launched in 2011 and conducted out of its CLIA-certified laboratory. Using existing biopsy tissue, the test identifies biomarkers that are associated with malignant cells in benign tissue. The firm is also developing tests for detecting breast cancer, bladder cancer, thyroid cancer, melanoma, ovarian cancer, pancreatic cancer, uterine cancer, and endometriosis, it said.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.